| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15651 R64625 |
Blotière (Indications other than epilepsy), 2019 | Gastroschisis | 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: No (among antiseizure medications) | 3.93 [0.25;63.09] C | 0/980 243/1,875,733 | 243 | 980 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15601 R64304 |
Tinker (Mixed indications), 2019 | Gastroschisis | 1st trimester | case control | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) | 0.78 [0.18;3.35] C | 2/23 1,398/12,910 | 1,400 | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S17865 R75463 |
Eros (Indications NOS), 2002 | Exomphalos/gastroschisis | during pregnancy (anytime or not specified) excluded | case control | unexposed (general population or NOS) | Adjustment: No BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Matched |
no data excluded (exposition period) |
0/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 2 studies | 1.12 [0.30;4.14] | 1,643 | 1,003 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Indications other than epilepsy; 2: Mixed indications;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded